January 25, 2023
RFA-HL-24-003 - Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Coordination Center (U24 Clinical Trial Not Allowed)
RFA-HL-24-004 - Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) (R25 Clinical Trial Not Allowed)
National Heart, Lung, and Blood Institute (NHLBI)
The National Heart, Lung, and Blood Institute (NHLBI) is announcing a correction to Section III. Eligibility Information regarding the number of applications allowed for RFA-HL-24-003 "Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) Coordination Center (U24 Clinical Trial Not Allowed)" and RFA-HL-24-004 “Programs for Inclusion and Diversity Among Individuals Engaged in Health-Related Research (PRIDE) (R25 Clinical Trial Not Allowed)”. Changes are shown for each funding opportunity announcement in bold italics below.
Currently reads in RFA-HL-24-003:
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed. Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
Institutions may apply for both the Summer Institute (RFA-HL-24-004) and CC components of this program. However, the PD(s)/PI(s) for the CC must not be the same PD(s)/PI(s) for the Summer Institute application.
Modified to read in RFA-HL-24-003 (changes shown in bold italics):
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.
Institutions may apply for both the Summer Institute (RFA-HL-24-004) and CC components of this program. However, the PD(s)/PI(s) for the CC must not be the same PD(s)/PI(s) for the Summer Institute application.
Currently reads in RFA-HL-24-004:
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Applicant organizations may submit more than one application, provided that each application is scientifically distinct.
The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review.
Modified to read in RFA-HL-24-004 (changes shown in bold italics):
Section III. Eligibility Information
3. Additional Information on Eligibility
Number of Applications
Only one application per institution (normally identified by having a unique UEI or NIH IPF number) is allowed.
The NIH will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:
- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
- An application that has substantial overlap with another application pending appeal of initial peer review.
All other aspects of RFA-HL-24-003 and RFA-HL-24-004 remain unchanged.
Inquiries
Please direct all inquiries regarding this Notice to:
Scientific/Research Contact(s)
Nicole Redmond, MD, PhD, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-435-0739
Email: [email protected]
and Human Services (HHS)
